Literature DB >> 9587131

Hemophagocytic syndrome in five patients with Epstein-Barr virus negative B-cell lymphoma.

T Ohno1, N Miyake, S Hada, Y Hirose, A Imura, T Hori, T Uchiyama, T Saiga, T Mizumoto, H Furukawa.   

Abstract

BACKGROUND: The recent recognition of the association of Epstein-Barr virus (EBV) with T-cell/natural killer cell (T/NK-cell) lymphoma has documented that particular types of EBV-containing T/NK-cell lymphoma are frequently complicated by hemophagocytic syndrome (HPS). This observation suggests that both EBV and proliferating T/NK-lymphoma cells play significant roles in the development of HPS. Cytokines released from neoplastic T cells are presumed to account for the activation of macrophages, which is followed by a complex cascade of cytokine production, resulting in full-blown HPS. Five patients with B-cell lymphoma complicated by HPS were studied for elevated serum cytokines, the association of EBV, and CD25 expression of lymphoma cells; the aim of this study was to verify whether the mechanisms of HPS development hypothesized for T/NK-cell lymphoma also operate in B-cell lymphoma.
METHODS: Sera were analyzed for the presence of inflammatory and immunoregulatory cytokines. Flow cytometry, immunohistology (IH), in situ hybridization (ISH), polymerase chain reaction (PCR), and Southern blot analysis were performed using bone marrow aspirates, biopsy specimens, and autopsy specimens.
RESULTS: Immunophenotypic and Southern blot studies verified that the lymphoma cells of all five patients were of B-cell lineage. Bone marrow aspirates demonstrated histiocytosis with extensive hemophagocytic activity. Marked elevation of serum cytokines and expression of CD25 were observed in all five patients. However, the results of PCR, ISH using EBER1 probe, and IH for latent membrane protein indicated that these lymphoma cells were free of EBV infection.
CONCLUSIONS: In patients with B-cell lymphoma, EBV infection is not necessarily required for the initiation of HPS. In this article, the pathogenesis of HPS assumed to be operative in B-cell lymphoma is discussed with reference to T/NK-cell lymphoma complicated by HPS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9587131

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  High levels of IL-10 and determination of other cytokines and chemokines in HIV-associated haemophagocytic syndrome.

Authors:  O Benveniste; N Dereuddre-Bosquet; P Clayette; C Leport; J L Vildé; D Dormont
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Prevalence of intravascular large B-cell lymphoma with bone marrow involvement at initial presentation.

Authors:  Masafumi Ito; Yonggoo Kim; Jong Weon Choi; Hiroaki Ozawa; Masahiko Fujino
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

3.  A unique bone marrow lymphoma patient presenting with an isolated mass: A case report.

Authors:  Yi-Wen Xu; Ming-Hui Duan
Journal:  Oncol Lett       Date:  2017-12-06       Impact factor: 2.967

4.  Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy.

Authors:  Tatsuharu Ohno; Takashi Sakamoto; Chisaki Mizumoto; Takashi Miyoshi; Maki Ueda; Tomoharu Takeoka; Kouhei Yamashita; Terutoshi Hishita; Shigefusa Hada
Journal:  Int J Hematol       Date:  2006-07       Impact factor: 2.490

5.  The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell/natural killer cell lymphomas.

Authors:  Tatsuharu Ohno; Yasunori Ueda; Ken-ichi Nagai; Takayuki Takahashi; Yoshiteru Konaka; Teruyuki Takamatsu; Takayo Suzuki; Masataka Sasada; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

6.  Systematic Epstein-Barr virus-positive T-cell lymphoproliferative disease presenting as a persistent fever and cough: a case report.

Authors:  Fereshteh Ameli; Firouzeh Ghafourian; Noraidah Masir
Journal:  J Med Case Rep       Date:  2014-08-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.